Showing results (131-140 of 181) with videos related to

Sort By:
Pageof 19
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
Pharmacogenetics and Genomics|February 28, 2020
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptivesDavid W Haas, Yoninah S Cramer, Catherine Godfrey, et al.
Pharmacogenetics and Genomics|August 9, 2021
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosisDavid W Haas, Rosie Mngqibisa, Jose Francis, et al.
British Journal of Clinical Pharmacology|February 9, 2024
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South AfricaRephaim Mpofu, Aida N Kawuma, Roeland E Wasmann, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in BrazilJacqueline A Piekos, Gustavo Amorim, Felipe Ridolfi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2021
A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment OutcomesLauren S Peetluk, Peter F Rebeiro, Felipe M Ridolfi, et al.
Human Genetics|January 6, 2026
Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in BrazilJacqueline A Piekos, Gustavo Amorim, Felipe Ridolfi, et al.
The Journal of Infectious Diseases|May 21, 2013
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmissionSaran Vardhanabhuti, Edward P Acosta, Heather J Ribaudo, et al.
Pharmacogenetics and Genomics|October 29, 2024
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohortGustavo Amorim, James Jaworski, Jing Yang, et al.
Pharmacogenetics and Genomics|February 17, 2025
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosisNia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, et al.
Pageof 19